1Whzig TE,Gordon LI,Cabanillas F,et al.Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade,follicular.Or transformed Bcell non-Hodgkin's lymphoma[J].J Clin Oncol,2002.20(10):2453 2463.
2Kaminski MS.Tuck M,Estes J,et al 131Ⅰ-tositumomab therapy as initial treatment for follicular lymphoma[J].N Engl J Med,2005,352(5):441-449
3Leo l,Arturo Molina,Thomas Witzig et al.Durable responses after ibritumomah tiuxetan radioimmunotherapy for CD+20 B-celllymphoma:long-term follow-up of a phase 1/2study[J].Blood,2004,103(12):4429-4431.
4Emmanouilidea C,Witzig TE.Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma[J].Leuk Lymphoma,2006,47(4):629-636.
5Nademanee A,Forman S,Molina A,et al.A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma[J].Blood,2005,106(8):2896-2902.
6Leonard JP,Coleman M,Kostakoglu L,et al.Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine Ⅰ-131 tositumomab for untreated follicular lymphoma.Proc Am Soc Clin Oneol,2004,Abstra No:6518[J].J Clin Onco1.2005,23:5696-5704.
7Kaminski MS.Radford JA,Gregory SA.Et al.Re-treatment with Ⅰ-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to Ⅰ-131 tositumomabl[J].J Clin Oncol,2005,23(31):7985-7993.
2Lee A W,Sze W M,Au J S,et al.Treatment results fonasopharyngeal carcinoma in the modern era:the Hong Kong experience[J].Int J Radiat Oncol Biol Phys,2005,61(4):1107-1116.
